Drug Shortage Report for ADENOSINE INJECTION
Report ID | 159836 |
Drug Identification Number | 02457482 |
Brand name | ADENOSINE INJECTION |
Common or Proper name | ADENOSINE INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | ADENOSINE |
Strength(s) | 3MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 4ML |
ATC code | C01EB |
ATC description | OTHER CARDIAC PREPARATIONS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2022-05-02 |
Estimated end date | |
Actual end date | 2022-06-30 |
Shortage status | Resolved |
Updated date | 2022-11-03 |
Company comments | Effective May 2, 2022, this product will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2022-11-03 | French | Compare |
v4 | 2022-11-03 | English | Compare |
v3 | 2022-05-03 | English | Compare |
v2 | 2022-05-02 | French | Compare |
v1 | 2022-05-02 | English | Compare |
Showing 1 to 5 of 5